Improving Care Pathway Using Simplified Digital Tools for Oncology Patients: a Multicenter "Before-and-after" Study
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jul 21, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a digital tool called Onco'nect, designed to help monitor and manage side effects for cancer patients receiving outpatient chemotherapy. The goal is to see if using this tool can improve how well patients follow their treatment plans and reduce unexpected side effects from chemotherapy. Over a period of 18 months, the study will include 480 patients aged 18 and older who are starting intravenous chemotherapy for solid tumors. Participants will be monitored both before and after the Onco'nect tool is implemented at their treatment center.
Eligible participants will need to be comfortable with the study and willing to share their medical data. They should not have any difficulties understanding or reading French, nor should they have any cognitive or psychiatric issues that might affect their participation. If you join the study, you can expect to use the Onco'nect tool as part of your care, and your experiences will help researchers understand how well this digital solution works in improving patient care.
Gender
ALL
Eligibility criteria
- • Inclusion criteria
- • Age \>=18 years
- * Initiation of I.V. chemotherapy for solid cancer of any location or metastatic status:
- • Either over a period of 12 months before Onco'nect is deployed, covering the year preceding the actual implementation of the solution in each centre.
- • Or over a period of 12 months post-deployment of Onco'nect, covering the year following the implementation of the solution within the centre.
- • Non-opposition to the study and to the processing of their medical data.
- • Exclusion criteria
- • Any known difficulty in understanding or reading French that might invalidate the relevance of applying questionnaires
- • Known cognitive or psychiatric disorder preventing the protocol from being carried out
- • Patient under legal protection
- • Patient included in the article 51 programme
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Christophe TOURNIGAND, MD-PhD
Principal Investigator
Assistance Publique - Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported